Inclusion Criteria:

          -  Patients with biopsy-proven metastatic solid tumor and be eligible to receive
             nivolumab per standard of care

          -  Patients will be allowed to have any number of prior lines of therapy for metastatic
             cancer

          -  Patients with measurable and non-measurable disease are allowed to participate

          -  Absolute neutrophil count (ANC) ? 1.5 x 10^3/mm^3

          -  Hemoglobin (Hgb) ? 9 g/dL

          -  Platelet count ? 100 x10^3/mm^3

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 2.5 x upper limit of
             normal (ULN) or ? 5 x ULN in patients with liver metastases

          -  Prothrombin time ? 1.5 x ULN

          -  Total bilirubin ? 1.5 x ULN (unconjugated bilirubin of < 3 x ULN for patients with
             known Gilbert syndrome)

          -  Creatinine clearance of ? 50 ml/min by Cockcroft-Gault equation

          -  Corrected QT interval of < 480 msec (using either Bazett?s or Fridericia's formula)

          -  Life expectancy of > 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 ? 2

          -  Sexually active women with child bearing potential must have a negative pregnancy test
             obtained within 14 days prior to initiating study treatment

          -  Sexually active women of child-bearing potential and men must agree to use adequate
             contraception prior to study entry, for the duration of study participation and for 3
             months after completion of study treatment administration; adequate contraception
             includes methods such as oral contraceptives, double barrier method (condom plus
             spermicide or diaphragm), or abstaining from sexual intercourse

        Exclusion Criteria:

          -  History of prior therapy with ibrutinib or nivolumab

          -  Unable to swallow capsules or having disease that is significantly affecting
             gastrointestinal function and/or inhibiting small intestine absorption

          -  Diagnosis of congenital or acquired immunodeficiency with the exception of
             chemotherapy induced immune suppression

          -  Active autoimmune disease requiring systemic treatment within the past 3 months or a
             documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids of greater than or equal to prednisone 10 mg/day or other
             immunosuppressive agents; patients with history of adequately treated Hashimoto?s
             thyroiditis will be eligible; patients requiring a short course of a high dose
             prednisone burst to treat asthma or common obstructive pulmonary disease will also be
             eligible 5 days following completion of the prednisone treatment

          -  Use of systemic steroids at a dose above 10 mg/day of prednisone or prednisone
             equivalent in cycle 1 of study therapy; systemic steroids must be discontinued at
             least 5 days prior to initiating study therapy; exception will be given to patients
             who develop immune related adverse events that necessitate use of steroids or other
             immune suppressive agents; following cycle 1 of study treatment, the use of systemic
             steroids will be allowed per discretion of the treating physician

          -  Active, non-infectious pneumonitis

          -  Ongoing or active infection requiring systemic therapy

          -  History of being positive for human immunodeficiency virus (HIV)

          -  History of hepatitis B or C

          -  History of receiving live vaccine within 30 days of planned start of study therapy

          -  Central nervous system (CNS) metastases or leptomeningeal carcinomatosis; patients
             with history of adequately treated brain metastases that are stable for > 2 weeks
             prior to the first dose of study regimen are eligible as long they no longer require
             steroids and have no seizures or worsening focal neurologic symptoms; anti-epileptic
             therapy will be allowed

          -  Patients who had prior systemic chemotherapy within 3 weeks (or < 5 half-lives ?
             whichever is longer)

          -  Prior radiation therapy within 2 weeks of study enrollment

          -  Prior investigational therapy within 4 weeks

          -  Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose
             of study drug; port placement will not be considered major or minor surgery

          -  Any inter-current, uncontrolled systemic illness or any medical or psychiatric
             condition that in the opinion of the investigator would make the study therapy unsafe
             to the patient

          -  Unable to understand and sign informed consent form

          -  Uncontrolled, active cardiovascular disease including, but not limited to: symptomatic
             congestive heart failure, any class 3 or 4 cardiac disease as defined by the New York
             Heart Association functional classification, unstable angina pectoris, cardiac
             arrhythmia

          -  Any medications or substances that are strong inhibitors or inducers of CYP 3A4 need
             to be discontinued prior to initiation the study therapy and for the duration of
             ibrutinib treatment; patients can resume these medications 3 days after completion of
             ibrutinib course

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition as ibrutinib or nivolumab